MedTrace Logo

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

NCT01377909 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-08-22

No results posted yet for this study

Summary

Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV.

Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

statin

daily statin orally for 48 weeks

Sponsors & Collaborators

  • Bader, Ted, M.D.

    lead INDIV

Principal Investigators

  • Ted Bader, M.D. · VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01377909 on ClinicalTrials.gov